プロトンポンプ阻害薬(PPI)の世界市場予測・分析:OTC PPI、処方PPI

Technavioが発行した調査報告書(IRTNTR31536)
◆英語タイトル:Proton Pump Inhibitors (PPIs) Market by Product and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR31536
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年6月24日
◆ページ数:127
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:Asia, Europe, North America, and ROW
◆産業分野:Health Care
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥318,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

Technavio社の本調査レポートでは、プロトンポンプ阻害薬(PPI)の世界市場について調べ、プロトンポンプ阻害薬(PPI)の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、プロトンポンプ阻害薬(PPI)の市場規模をセグメンテーション別(製品別(OTC PPI、処方PPI)、)と地域別(Asia, Europe, North America, and ROW)に分けて算出しました。Technavio社はプロトンポンプ阻害薬(PPI)の世界市場規模が2019-2023期間中に年平均4%成長すると予測しています。
・サマリー
・レポートの範囲
・プロトンポンプ阻害薬(PPI)の市場状況
・プロトンポンプ阻害薬(PPI)の市場規模
・プロトンポンプ阻害薬(PPI)の市場予測
・プロトンポンプ阻害薬(PPI)の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(OTC PPI、処方PPI)
・プロトンポンプ阻害薬(PPI)の顧客状況
・主要地域別市場規模:Asia, Europe, North America, and ROW
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Proton Pump Inhibitors (PPIs) Market: About this market

Proton pump inhibitors (PPIs) are drugs whose main mechanism is to inhibit the secretion of acid by the stomach, thus helping in reducing the symptoms of various acid-related diseases. Technavio’s proton pump inhibitors (PPIs) market analysis considers sales from Over-the-counter (OTC) PPIs and prescription PPIs. Our analysis also considers the sales of proton pump inhibitors (PPIs) in Asia, Europe, North America, and ROW. In 2018, the OTC PPIs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as easy accessibility and affordability of OTC drugs will play a significant role in the OTC PPIs segment to maintain its market position. Also, our global proton pump inhibitors (PPIs) market report looks at factors such as reformulation of drugs and growth in prescription rates. However, the increasing lawsuits against PPIs, launch of generic PPIs, and stringent regulatory guidelines may hamper the growth of the proton pump inhibitors (PPIs) industry over the forecast period.

Global Proton Pump Inhibitors (PPIs) Market: Overview

Reformulation of drugs

Vendors are trying to maintain their positions in the market by delaying the entry of generic versions and obtaining patent extensions through reformulation of drugs. This ensures the bioavailability of drugs and boosts patient compliance. The reformulation of already marketed drugs by vendors will lead to the expansion of the global proton pump inhibitors (PPIs) market at a CAGR of over 4% during the forecast period.

Rising prevalence of obesity

With the prevalence of obesity in older adults and children and adolescents, the risks to develop chronic diseases such as type 2 diabetes, cardiovascular diseases, and certain types of cancer is also increasing. This is driving the need for PPIs for the treatment of these diseases, which is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global proton pump inhibitors (PPIs) market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global proton pump inhibitors (PPIs) market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proton pump inhibitors (PPIs) manufacturers, that include AstraZeneca Plc, Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the proton pump inhibitors (PPIs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

OTC PPIs – Market size and forecast 2018-2023

Prescription PPIs – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Growing geriatric population

Rising prevalence of obesity

Rising utilization of PPIs

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

AstraZeneca Plc

Bayer AG

Johnson & Johnson Services Inc.

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Product – Market share 2018-2023 (%)

Exhibit 18: Comparison by product

Exhibit 19: OTC PPIs – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: OTC PPIs – Year-over-year growth 2019-2023 (%)

Exhibit 21: Prescription PPIs – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Prescription PPIs – Year-over-year growth 2019-2023 (%)

Exhibit 23: Market opportunity by product

Exhibit 24: Customer landscape

Exhibit 25: Market share by geography 2018-2023 (%)

Exhibit 26: Geographic comparison

Exhibit 27: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: North America – Year-over-year growth 2019-2023 (%)

Exhibit 29: Top 3 countries in North America

Exhibit 30: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in Europe

Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Asia

Exhibit 36: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in ROW

Exhibit 39: Key leading countries

Exhibit 40: Market opportunity

Exhibit 41: Use of PPIs in different patient settings in 2010

Exhibit 42: Sales of Takeda’s PPIs after the launch of generics ($ millions)

Exhibit 43: Impact of drivers and challenges

Exhibit 44: Vendor landscape

Exhibit 45: Landscape disruption

Exhibit 46: Vendors covered

Exhibit 47: Vendor classification

Exhibit 48: Market positioning of vendors

Exhibit 49: AstraZeneca Plc – Vendor overview

Exhibit 50: AstraZeneca Plc – Product segments

Exhibit 51: AstraZeneca Plc – Organizational developments

Exhibit 52: AstraZeneca Plc – Geographic focus

Exhibit 53: AstraZeneca Plc – Key offerings

Exhibit 54: AstraZeneca Plc – Key customers

Exhibit 55: Bayer AG – Vendor overview

Exhibit 56: Bayer AG – Product segments

Exhibit 57: Bayer AG – Organizational developments

Exhibit 58: Bayer AG – Geographic focus

Exhibit 59: Bayer AG – Segment focus

Exhibit 60: Bayer AG – Key offerings

Exhibit 61: Bayer AG – Key customers

Exhibit 62: Johnson & Johnson Services Inc. – Vendor overview

Exhibit 63: Johnson & Johnson Services Inc. – Business segments

Exhibit 64: Johnson & Johnson Services Inc. – Organizational developments

Exhibit 65: Johnson & Johnson Services Inc. – Geographic focus

Exhibit 66: Johnson & Johnson Services Inc. – Segment focus

Exhibit 67: Johnson & Johnson Services Inc. – Key offerings

Exhibit 68: Johnson & Johnson Services Inc. – Key customers

Exhibit 69: Pfizer Inc. – Vendor overview

Exhibit 70: Pfizer Inc. – Business segments

Exhibit 71: Pfizer Inc. – Organizational developments

Exhibit 72: Pfizer Inc. – Geographic focus

Exhibit 73: Pfizer Inc. – Segment focus

Exhibit 74: Pfizer Inc. – Key offerings

Exhibit 75: Pfizer Inc. – Key customers

Exhibit 76: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 77: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 78: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 79: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 80: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 81: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 82: Validation techniques employed for market sizing

Exhibit 83: Definition of market positioning of vendors



【掲載企業】

AstraZeneca Plc
Bayer AG
Johnson & Johnson Services Inc.
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ プロトンポンプ阻害薬(PPI)の世界市場予測・分析:OTC PPI、処方PPI(Proton Pump Inhibitors (PPIs) Market by Product and Geography - Global Forecast and Analysis 2019-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆